The Epilepsy‐Desirability of Outcome Ranking ( <scp>DOOR</scp> ) as a Multi‐Faceted Consumer‐Informed Outcome Measure for Epilepsy Clinical Trials
Epilepsy-DOOR showed similar effect sizes but slightly reduced power when compared with responder rate. This reduced power is due to the appropriate reflection of adverse events by Epilepsy-DOOR. Epilepsy-DOOR provides a more holistic measure of anti-seizure medication treatment effects, balancing relative benefits and harms, and has potential as a future endpoint in clinical trials in epilepsy.
Authors
- Leonid P. Churilov (ORCID: https://orcid.org/0000-0002-9807-6606)
- Hannah Tabitha Johns (ORCID: https://orcid.org/0000-0003-2135-0504)
- Lucy E. Vivash (ORCID: https://orcid.org/0000-0002-1182-0907)
- Terence O′Brien
Institutions
- The Royal Melbourne Hospital (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/ene.70531
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government
- National Health and Medical Research Council